Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC

Clinical trial NCT06690541 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06690541
Sponsor: Peking University Cancer Hospital & Institute
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL

Lung Cancer, Non-Small Cell

Start date: 2024-11-10
Primary completion: 2027-04-30
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.